SNV1521 in Participants with Advanced Solid Tumors

Description

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Conditions

Advanced Solid Tumor

Study Overview

Study Details

Study overview

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors

SNV1521 in Participants with Advanced Solid Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale University, New Haven, Connecticut, United States, 06520

Philadelphia

Thomas Jefferson University, Philadelphia, Pennsylvania, United States, 19144

Nashville

Sarah Cannon Research Institute, Nashville, Tennessee, United States, 37203

Houston

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States, 77030

West Valley City

START Center for Cancer Care, West Valley City, Utah, United States, 84119

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Advanced or metastatic solid tumor malignancy
  • * Evaluable or Measurable disease (RECIST 1.1 Criteria).
  • * ECOG Performance Status 0 or 1.
  • * Life expectancy \> 3 months
  • * History of other malignancy within the past 2 years
  • * Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
  • * Significant cardiovascular disease within 6 months
  • * Significant gastrointestinal disease
  • * HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
  • * Liver dysfunction

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Synnovation Therapeutics, Inc.,

Study Record Dates

2026-12